J&J to invest €100 million into Limerick manufacturing facilities creating 100 new jobs

pharmafile | May 16, 2019 | News story | Manufacturing and Production Ireland, J&J, JJ, Limerick, medical technology, pharma 

Healthcare conglomerate Johnson & Johnson has said it will be investing €100 million into the expansion of its Vision Care manufacturing facilities in Limerick. The expansion is expected to see the creation of 100 new jobs.

The Minister of State for Trade, Employment and Business, Deputy Pat Breen celebrated the investment in calling it a “huge vote of confidence” in Ireland’s mid-west.

“The expansion, supported by the Government through the IDA, reflects the commitment of the Government and its agencies to pursue balanced and sustainable regional development,” Minister Breen said.

“We believe that the new manufacturing roles being introduced in Limerick in 2019 will be foundational in helping us bring new, innovative contact lens products to our patients and customers around the world at an industry-leading pace,” Vision Care’s plant leader, John Lynch said.

The CEO of IDA Ireland – the agency responsible for attracting and retaining foreign investment – Martin Shanahan commented: “The approximately 100 jobs being added, along with those being created in the construction phase, will greatly benefit the economy of the Mid-West region.

“Having a company of this stature continue to expand its operations enhances Ireland’s global reputation as a Medical Technologies centre of excellence and demonstrates how global companies can successfully operate in regional locations. I wish John and his team continued success.”

Louis Goss

Related Content

New warning added to J&J vaccine in US

The FDA has made the decision to add a warning to the fact sheet for …

J&J’s Tremfya sees positive results for post-TNFi psoriatic arthritis

Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Latest content